GENELUX

Genelux initiated Phase II VIRO-25 trial in the US to evaluate systemic Olvi-Vec for recurrent NSCLC, enrolling patients unresponsive to platinum-based and ICI therapies. The trial compares Olvi-Vec plus platinum-doublet chemotherapy and ICI against docetaxel in advanced or metastatic NSCLC patients. Previous studies showed Olvi-Vec's manageable safety profile, and the trial aims to validate its potential in resensitising patients to platinum therapies. Interim data is expected mid-next year.